ReviewPediatric nephrology (Berlin, Germany)2008
Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?
Review in Pediatric nephrology (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.Pediatric nephrology (Berlin, Germany) · 2008Trial
- Transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of pediatric nephrotic syndrome: a pilot study.Bioelectronic medicine · 2022Article
- Vagus Nerve Stimulation: A Potential Therapeutic Role in Childhood Nephrotic Syndrome?American journal of nephrology · 2022Article
- Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.Pediatric nephrology (Berlin, Germany) · 2018Review
- Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.Scientific reports · 2017Article
- Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.World journal of pediatrics : WJP · 2015Review
- Is rituximab effective in childhood nephrotic syndrome? Yes and no.Pediatric nephrology (Berlin, Germany) · 2014Review
- Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?Pediatric nephrology (Berlin, Germany) · 2013Article
- Characterisation of renal immune cell infiltrates in children with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Article
- Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.Pediatric nephrology (Berlin, Germany) · 2010Article
- Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura.Pediatric nephrology (Berlin, Germany) · 2009Article
- Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2009Article
- Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution.Pediatric nephrology (Berlin, Germany) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anti-CD20 antibody rituximab has been used successfully as a rescue therapy in some patients with therapy-refractory steroid-dependent nephrotic syndrome (SDNS), including both primary SDNS with minimal changes on biopsy and recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation. All patients showed remission from steroid dependency for at least 9 months concurring with the reappearance of B lymphocytes that had been eliminated by rituximab. The doses used so far vary between 375 mg/m(2) per dose at weekly intervals for 6 weeks and a single dose of 375 mg/m(2). Until now, with the limited information available, no substantial adverse effects have been reported. However, a recommendation to use rituximab instead of any other established treatment, such as cyclophosphamide, in SDNS cannot be given before clinical studies have been conducted, especially as publication bias cannot be excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.